Company news
Capricor Therapeutics, Inc. (NASDAQ:CAPR) news
Every Capricor Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
August 24, 2026
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
July 30, 2026
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
July 29, 2026
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
June 26, 2026
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2...
June 26, 2026
Capricor Therapeutics : Expands Commercial Leadership Team
May 28, 2026
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
May 4, 2026
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Mee...
April 22, 2026
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
March 23, 2026
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Der...
March 12, 2026
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
March 10, 2026
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
March 9, 2026
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
February 24, 2026
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
January 20, 2026
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duche...
December 16, 2025
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
December 5, 2025
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
December 4, 2025
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
December 3, 2025
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV...
November 24, 2025
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investig...
November 3, 2025
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
October 31, 2025
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
September 25, 2025
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
September 9, 2025
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
August 18, 2025
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
August 8, 2025
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
August 6, 2025
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for t...
July 28, 2025
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
July 11, 2025
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
June 20, 2025
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystr...
June 17, 2025
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
June 11, 2025
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
May 13, 2025
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
May 6, 2025
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dyst...
May 5, 2025
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
April 1, 2025
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 19, 2025
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystr...
March 17, 2025
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
March 11, 2025
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
March 10, 2025
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
March 7, 2025
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne ...
March 4, 2025
Capricor Therapeutics to Participate in Upcoming Investor Conferences
February 10, 2025
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne ...
January 2, 2025
Capricor Therapeutics to Present at Upcoming Investor Conferences
December 2, 2024